PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsRezafungin
Rezafungin
Rezzayo (rezafungin) is a small molecule pharmaceutical. Rezafungin was first approved as Rezzayo on 2023-03-22. It is used to treat candidemia and invasive candidiasis in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Rezzayo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rezafungin acetate
Tradename
Company
Number
Date
Products
REZZAYOCidara TherapeuticsN-217417 RX2023-03-22
1 products, RLD, RS
Labels
FDA
EMA
No data
Indications
FDA
EMA
Agency Specific
FDA
EMA
Expiration
Code
REZAFUNGIN ACETATE, REZZAYO, CIDARA THERAPS
2035-03-22GAIN
2033-03-22GAIN
2030-03-22ODE-426
2028-03-22NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Rezafungin Acetate, Rezzayo, Cidara Theraps
111979092038-07-14DS, DPU-3566
118195332038-07-11DS, DPU-3566
117124592037-03-15DPU-3566
95268352033-03-14DS, DPU-3566
107025732033-03-14DS, DPU-3566
87226192032-03-02DS, DPU-3566
116541962032-03-02DS, DPU-3566
ATC Codes
J: Antiinfectives for systemic use
— J02: Antimycotics for systemic use
— J02A: Antimycotics for systemic use
— J02AX: Other antimycotics for systemic use in atc
— J02AX08: Rezafungin acetate
HCPCS
No data
Clinical
Clinical Trials
8 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MycosesD009181—B35-B49122——5
CandidemiaD058387EFO_1001282——12——3
Invasive candidiasisD058365EFO_1001283B37—12——3
FungemiaD016469—B49—11——2
PneumocystisD011010————1——1
AspergillusD001230————1——1
Invasive hydatidiform moleD002820—D39.2——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Vulvovaginal candidiasisD002181EFO_0007543B37.3—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———2————2
Invasive fungal infectionsD000072742——1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRezafungin
INNrezafungin acetate
Description
Rezafungin, sold under the brand name Rezzayo, is a medication used for the treatment of invasive candidiasis. It is an echinocandin antifungal.
Classification
Small molecule
Drug classantifungal antibiotics (undefined group)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](OCC[N+](C)(C)C)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)cc5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)cc2)cc1
Identifiers
PDB—
CAS-ID1396640-59-7
RxCUI—
ChEMBL IDCHEMBL3989945
ChEBI ID—
PubChem CID78318119
DrugBankDB16310
UNII IDW1U1TMN677 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,351 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use